🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12213977

    Methods and compositions for treating melanoma

    The Regents of the University of California · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12203098

    Cells having solid tumor targeting backbone and use thereof

    Fate Therapeutics, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12195447

    Azolopyrimidine for the treatment of cancer-related disorders

    Arcus Biosciences, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12195804

    Treatment of squamous cell carcinoma

    The Board of Regents of the University of Texas System · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12195766

    Tumor-selective E1a and E1b mutants

    The Regents of the University of California · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12186428

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12187992

    Method and device for early cancer screening

    The Regents of the University of California · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12187792

    IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12188048

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12186378

    Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12188005

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12186342

    Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha

    The Regents of the University of California · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12187782

    PDL1 peptides for use in cancer vaccines

    IO Biotech ApS · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12178887

    NIR-conjugated tumor-specific antibodies and uses thereof

    The Regents of the University of California · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12180296

    Cross species single domain antibodies targeting mesothelin for treating solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12174192

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12171818

    Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12171765

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12168054

    Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

    Syndax Pharmaceuticals, Inc. · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12161607

    Combination of cannabinoids in the treatment of leukemia

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12161706

    Cancer vaccines targeting BORIS and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12161733

    Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12162877

    Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation

    DRUG DISCOVERY AND CLINIC S.R.L. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12162950

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12162855

    Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12161724

    Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens

    JANUX THERAPEUTICS, INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12162870

    Anticancer compounds

    The Regents of the University of California · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12156863

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12144809

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12146139

    Oligonucleotide interference treatments of prostate cancer

    The Board of Regents of the University of Oklahoma · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12145925

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12139764

    Systems and methods for characterizing and treating breast cancer

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12134650

    Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12122846

    Chimeric antigen receptor for tumor targeting

    Fate Therapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12121522

    Methods of treating cancer with an mTOR inhibitor

    Revolution Medicines, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12121288

    Combination tumor treatment

    Regents of the University of Minnesota · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12116635

    Methods for detecting and treating cancers having adenosine pathway activation

    Corvus Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12116637

    Compositions and methods for detecting and treating high grade subtypes of uterine cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12116375

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Corcept Therapeutics Incorporated · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.